The Cambridge Crystallographic Data Centre (CCDC) partnered with Intel and AWS to accelerate drug development by enhancing the Cambridge Structural Database (CSD), which holds over 1.1 million small molecule structures. Their goal was to support drug discovery by improving understanding of hydrogen bonding in protein-ligand complexes. Using Intel® Xeon® Scalable processors on Amazon EC2, CCDC refined atomic positions of hydrogen atoms and built a public-facing protein structure database. This collaboration drastically reduced optimization time, enabling rapid access to refined data and saving researchers significant time globally.

Join for free to read